{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:32:01Z","timestamp":1763105521620,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.urolonc.2017.03.010","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T11:30:18Z","timestamp":1493119818000},"page":"532.e1-532.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"Per-Uno","family":"Malmstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammer","family":"Hemdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrika","family":"Segersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.03.010_bib1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.03.010_bib3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2008.09.062","article-title":"Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Gu\u00e9rin","volume":"56","author":"Palou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2012.05.033","article-title":"Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer","volume":"65","author":"Bertz","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.urology.2010.04.040","article-title":"Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with non\u2013muscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy","volume":"76","author":"Seo","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.03.010_bib7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1464-410X.2012.10996.x","article-title":"Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer","volume":"110","author":"van Rhijn","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.03.010_bib8","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.juro.2013.11.005","article-title":"Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Gu\u00e9rin with epirubicin and interferon-\u03b12b in patients with T1 bladder cancer","volume":"191","author":"Hemdan","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in nonmuscle invasive bladder cancer:it is time for a new, standard definition","volume":"191","author":"Lamm","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2490-14-36","article-title":"Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts","volume":"12","author":"Andersson","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables over estimate the risk of recurrence and progression in patients with non\u2013muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin:external validation of the EORTC risk tables","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacilli Calmette-Gu\u00e9rin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2017.03.010_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.urolonc.2011.06.004","article-title":"Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?","volume":"31","author":"Park","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib15","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-09-3323","article-title":"Gene signatures for the prediction of response to bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers","volume":"16","author":"Kim","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2017.03.010_bib16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bju.12844","article-title":"The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Gu\u00e9rin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population","volume":"116","author":"Lima","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2017.03.010_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Gu\u00e9rin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2017.03.010_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","article-title":"A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma","volume":"68","author":"Patschan","year":"2015","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917301102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917301102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:11:32Z","timestamp":1761041492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917301102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1078143917301102"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.03.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the ezrin, CK20, and Ki-67 as potential predictive markers for BCG instillation therapy of non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}